Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Study Title
A Phase 1, Single Dose, Parallel Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-44749, Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use, in Chinese Patients with Schizophrenia
Teva Identifier
TV44749-PK-10188
ClinicalTrials.gov Identifier
NCT06253546
Study Status
Recruiting
Trial Condition(s)
Schizophrenia
Interventions
Drug: TV-44749

Study Description

The primary objective is to evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia.
Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 64 Years
Trial Duration
March 28, 2024 - June 10, 2025
Phase
Phase 1

Study Type

Interventional